Q1 EPS Estimates for Vera Therapeutics Raised by Wedbush

Vera Therapeutics, Inc. (NASDAQ:VERA) – Equities researchers at Wedbush increased their Q1 2025 earnings per share (EPS) estimates for shares of Vera Therapeutics in a report released on Thursday, February 27th. Wedbush analyst L. Chico now expects that the company will post earnings per share of ($0.72) for the quarter, up from their prior forecast of ($0.81). Wedbush has a “Neutral” rating and a $38.00 price target on the stock. The consensus estimate for Vera Therapeutics’ current full-year earnings is ($2.89) per share. Wedbush also issued estimates for Vera Therapeutics’ Q2 2025 earnings at ($0.73) EPS, Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($3.20) EPS, FY2026 earnings at ($3.58) EPS, FY2027 earnings at ($2.08) EPS and FY2028 earnings at $0.20 EPS.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.11.

VERA has been the subject of a number of other research reports. The Goldman Sachs Group initiated coverage on Vera Therapeutics in a research note on Tuesday, January 28th. They issued a “buy” rating and a $58.00 target price for the company. Wells Fargo & Company assumed coverage on Vera Therapeutics in a research report on Thursday, November 21st. They set an “overweight” rating and a $70.00 price target on the stock. JPMorgan Chase & Co. cut their price target on Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a research report on Tuesday. Guggenheim increased their price target on Vera Therapeutics from $59.00 to $61.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. Finally, Wolfe Research assumed coverage on Vera Therapeutics in a research report on Tuesday, February 4th. They set an “outperform” rating and a $49.00 price target on the stock. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $64.67.

Vera Therapeutics Stock Performance

Shares of VERA stock opened at $28.60 on Monday. The firm has a market capitalization of $1.81 billion, a price-to-earnings ratio of -10.96 and a beta of 1.11. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. The business has a fifty day moving average of $35.21 and a 200 day moving average of $40.22. Vera Therapeutics has a 1 year low of $25.99 and a 1 year high of $51.61.

Insider Activity

In other news, CEO Marshall Fordyce sold 17,500 shares of the firm’s stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $41.74, for a total transaction of $730,450.00. Following the sale, the chief executive officer now directly owns 143,603 shares in the company, valued at $5,993,989.22. This trade represents a 10.86 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 52,500 shares of company stock worth $2,305,625 in the last ninety days. Company insiders own 21.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Huntington National Bank purchased a new position in Vera Therapeutics in the 4th quarter valued at about $26,000. AlphaQuest LLC purchased a new position in Vera Therapeutics in the 4th quarter valued at about $34,000. GF Fund Management CO. LTD. purchased a new position in Vera Therapeutics in the 4th quarter valued at about $56,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Vera Therapeutics by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company’s stock valued at $86,000 after buying an additional 350 shares in the last quarter. Finally, KBC Group NV lifted its stake in Vera Therapeutics by 127.2% in the 4th quarter. KBC Group NV now owns 2,477 shares of the company’s stock valued at $105,000 after buying an additional 1,387 shares in the last quarter. 99.21% of the stock is owned by hedge funds and other institutional investors.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.